Lunai Bioworks (LNAI) Non-Current Assets (2012 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Non-Current Assets of $6.1 million in Q1 2026, little changed quarter-over-quarter from $6.2 million in Q4 2025, and down 94.63% on a YoY basis from $114.1 million in Q1 2025.
Lunai Bioworks (LNAI) Non-Current Assets (2012 - 2026) Analysis & Trends
Lunai Bioworks' Non-Current Assets history runs 15 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 94.63% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $25.6 million (down 94.92% YoY), while the FY2025 annual figure was $7.2 million, down 95.54% from the prior year.
- Non-Current Assets was $6.1 million for Q1 2026 at Lunai Bioworks, roughly flat from $6.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $176.9 million in Q1 2024 to a low of $6.1 million in Q1 2026.
- Historically, Non-Current Assets has averaged $79.0 million across 5 years, with a median of $74.9 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets jumped 189.1% in 2024, then sank 95.54% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $74.9 million in 2022, then declined by 25.73% to $55.6 million in 2023, then soared by 97.13% to $109.6 million in 2024, then plunged by 94.39% to $6.2 million in 2025, then slipped by 0.39% to $6.1 million in 2026.
- The last three Non-Current Assets figures came in at $6.1 million (Q1 2026), $6.2 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.13 Mn |
| Dec 31, 2025 | 6.15 Mn |
| Sep 30, 2025 | 6.16 Mn |
| Jun 30, 2025 | 7.18 Mn |
| Mar 31, 2025 | 114.06 Mn |
| Dec 31, 2024 | 109.63 Mn |
| Sep 30, 2024 | 119.88 Mn |
| Jun 30, 2024 | 161.13 Mn |
| Mar 31, 2024 | 176.87 Mn |
| Dec 31, 2023 | 55.61 Mn |
| Sep 30, 2023 | 55.66 Mn |
| Jun 30, 2023 | 55.74 Mn |
| Mar 31, 2023 | 74.80 Mn |
| Dec 31, 2022 | 74.88 Mn |
| Sep 30, 2022 | 74.94 Mn |
| Jun 30, 2022 | 75.07 Mn |
| Mar 31, 2022 | 168.40 Mn |
| Dec 31, 2021 | 168.52 Mn |
| Sep 30, 2021 | 168.61 Mn |
| Jun 30, 2021 | 168.71 Mn |